COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE plus DOCETAXEL VS GEMCITABINE plus DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE

被引：0
|
作者：
Tenorio, C. [1 ]
Vargas, J. [2 ]
Martinez, J. [3 ]
机构：
[1] Inst Nacl Cancerol, Mexico City, DF, Mexico
[2] Econopharma Consulting SA CV, Mexico City, DF, Mexico
[3] Econopharma, Mexico City, DF, Mexico
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(10)74330-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A271 / A271
页数：1
相关论文
共 50 条
  • [21] CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
    Zhou, Xinna
    Qiao, Guoliang
    Wang, Xiaoli
    Song, Qingkun
    Morse, Michael A.
    Hobeika, Amy
    Gwin, William R.
    Ren, Jun
    Lyerly, H. Kim
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 365 - 372
  • [22] CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
    Xinna Zhou
    Guoliang Qiao
    Xiaoli Wang
    Qingkun Song
    Michael A. Morse
    Amy Hobeika
    William R. Gwin
    Jun Ren
    H. Kim Lyerly
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 365 - 372
  • [23] Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer
    Wenzel, C
    Bartsch, R
    Locker, GJ
    Hussian, D
    Pluschnig, U
    Sevelda, U
    Gnant, MF
    Jakesz, R
    Zielinski, CC
    Steger, GG
    ANTI-CANCER DRUGS, 2005, 16 (04) : 441 - 445
  • [24] A randomized controlled Phase II trial of vinorelbine plus capecitabine versus docetaxel plus capecitabine in anthracycline-pretreated women with metastatic breast cancer
    Li, Shufen
    Meng, Wenjing
    Zhang, Jibo
    Xie, Xiaojuan
    Hao, Chunfang
    Jia, Yongsheng
    Tong, Zhongsheng
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 1069 - 1076
  • [25] Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China
    Liao, Mengting
    Jiang, Qin
    Hu, Huabin
    Han, Jiaqi
    She, Longjiang
    Yao, Linli
    Ding, Dong
    Huang, Jin
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (06) : 584 - 592
  • [26] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    Stemmler, H. J.
    diGioia, D.
    Freier, W.
    Tessen, H. W.
    Gitsch, G.
    Jonat, W.
    Brugger, W.
    Kettner, E.
    Abenhardt, W.
    Tesch, H.
    Hurtz, H. J.
    Roesel, S.
    Brudler, O.
    Heinemann, V.
    BRITISH JOURNAL OF CANCER, 2011, 104 (07) : 1071 - 1078
  • [27] Phase III trial of gemcitabine plus docetaxel (GD) compared to capecitabine plus docetaxel (CD) with planned crossover to the alternate single agent in metastatic breast cancer (MBC)
    Seidman, A. D.
    Brufsky, A.
    Ansari, R. H.
    Rubinsak, J. R.
    Stein, R. S.
    Schwartzberg, L. S.
    Stewart, J. F.
    Zhao, L.
    Gill, J.
    Tai, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15) : CP48 - U410
  • [28] Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer
    H J Stemmler
    D diGioia
    W Freier
    H W Tessen
    G Gitsch
    W Jonat
    W Brugger
    E Kettner
    W Abenhardt
    H Tesch
    H J Hurtz
    S Rösel
    O Brudler
    V Heinemann
    British Journal of Cancer, 2011, 104 : 1071 - 1078
  • [29] Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
    Frias, Carmen
    Cortes, Javier
    Angel Segui, Miguel
    Oyagueez, Itziar
    Angel Casado, Miguel
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (10): : 692 - 700
  • [30] Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain
    Carmen Frías
    Javier Cortés
    Miguel Ángel Seguí
    Itziar Oyagüez
    Miguel Ángel Casado
    Clinical and Translational Oncology, 2010, 12 : 692 - 700
12345